Rep. James Comer (R-Ky.), ranking member of the House Committee on Oversight and Reform, on Friday issued a report outlining how PBM practices increase prescription drug prices, affect patient health, hurt competition, and distort the marketplace. The report, “A View from Congress: The Role of Pharmacy Benefit Managers in Pharmaceutical Markets,” details findings from a recent forum Comer held to examine how PBM tactics contribute to the rising cost of prescription drugs for Americans. NCPA member Jonathan Grider testified at the forum. Overall, the report emphasizes the need for greater transparency to determine the extent of the damage PBM practices are having on patients and the marketplace and calls for further congressional review of legislative solutions to provide meaningful reform. House Democrats on the Oversight Committee released their own report, calling drug-pricing tactics “unsustainable, unjustified and unfair,” but their attack focused on pharmaceutical companies.
NCPA
